Biomerica Announces Fiscal Year End 2019 Financial Results
30 août 2019 08h30 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
08 avr. 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Why IBS Affects Women Differently: A Capital Digestive Care GI Explains
26 févr. 2019 08h24 HE
|
Capital Digestive Care
Silver Spring, MD, Feb. 26, 2019 (GLOBE NEWSWIRE) -- By Leigh Lurie, MD IBS (irritable bowel syndrome) affects about 10% of the global population, making it the most common GI disorder in the...
Why You Could Have Celiac Disease Without Knowing It
12 sept. 2018 12h49 HE
|
Capital Digestive Care
Rockville, MD, Sept. 12, 2018 (GLOBE NEWSWIRE) -- By Brian Ciampa, MD Celiac disease is an autoimmune disorder affecting at least three million Americans, but it can be a difficult illness to pin...
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12 sept. 2018 07h00 HE
|
RedHill Biopharma Ltd.
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders ...
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
15 août 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
02 août 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...
AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands
28 juin 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 28, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company will be...
Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy
25 juin 2018 08h19 HE
|
Biomerica, Inc.
Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptomsApproximately 45 million Americans suffer from IBS1 Studies...
RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018
30 mai 2018 08h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty...